Reliability of functional outcome measures in adults with neurofibromatosis 1
- PMID: 30046444
- PMCID: PMC6056787
- DOI: 10.1177/2050312118786860
Reliability of functional outcome measures in adults with neurofibromatosis 1
Abstract
Objectives: To determine intra-rater and inter-rater reliability of functional outcome measures in adults with neurofibromatosis 1 and to ascertain how closely objective and subjective measures align.
Methods: A total of 49 ambulant adults with neurofibromatosis 1 aged 16 years and over were included in this observational study: median age 31 years (range: 16-66 years), 29 females, 20 males. Participants were video-recorded or photographed performing four functional outcome measures. Four raters from the neurofibromatosis centre multi-disciplinary team independently scored the measures to determine inter-rater reliability. One rater scored the measures a second time on a separate occasion to determine intra-rater reliability. The measures evaluated were the functional reach, timed up and go, 10 m walk and a modified nine-hole peg tests. Participants also completed a disease-specific quality-of-life questionnaire.
Results: Inter-rater reliability and intra-rater reliability scores (intra-class coefficient) were similar for each outcome measure. Excellent rater agreement (intra-class coefficient, r ⩾ 0.9) was found for the functional reach, timed up and go and the 10 m walk tests. Rater agreement was good for the modified nine-hole peg test: intra-class coefficient r = 0.75 for intra-rater reliability and 0.76 for inter-rater reliability. The timed up and go and the 10 m walk tests correlated highly with perceived mobility challenges in the quality-of-life questionnaire.
Conclusion: The functional reach, timed up and go and 10 m walk tests are potentially useful outcome measures for monitoring neurofibromatosis 1 treatment and will be assessed in multi-centre and longitudinal studies.
Keywords: Neurofibromatosis 1; minimal detectable change; outcome measure; rater reliability; standard error measurement.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Reliability of functional outcome measures in adults with neurofibromatosis 2.SAGE Open Med. 2022 Aug 19;10:20503121221118996. doi: 10.1177/20503121221118996. eCollection 2022. SAGE Open Med. 2022. PMID: 36003079 Free PMC article.
-
Reliability and agreement of the timed up and go test in children and teenagers with autism spectrum disorder.Eur J Pediatr. 2023 Aug;182(8):3577-3585. doi: 10.1007/s00431-023-05027-8. Epub 2023 May 25. Eur J Pediatr. 2023. PMID: 37227499 Free PMC article.
-
Remote administration of physical performance tests among persons with and without a cancer history: Establishing reliability and agreement with in-person assessment.J Geriatr Oncol. 2022 Jun;13(5):691-697. doi: 10.1016/j.jgo.2022.02.002. Epub 2022 Feb 15. J Geriatr Oncol. 2022. PMID: 35177378 Free PMC article.
-
The inter and intra rater reliability of the Netball Movement Screening Tool.J Sci Med Sport. 2015 May;18(3):353-7. doi: 10.1016/j.jsams.2014.05.008. Epub 2014 May 23. J Sci Med Sport. 2015. PMID: 24930074
-
Validity and reliability of Glittre activities of daily living test in lower-limb prosthetic users.Prosthet Orthot Int. 2024 Dec 24. doi: 10.1097/PXR.0000000000000422. Online ahead of print. Prosthet Orthot Int. 2024. PMID: 39721062
Cited by
-
Reliability of functional outcome measures in adults with neurofibromatosis 2.SAGE Open Med. 2022 Aug 19;10:20503121221118996. doi: 10.1177/20503121221118996. eCollection 2022. SAGE Open Med. 2022. PMID: 36003079 Free PMC article.
-
Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromes.Neurooncol Adv. 2020 Jun 25;2(Suppl 1):i134-i140. doi: 10.1093/noajnl/vdaa017. eCollection 2020 Jul. Neurooncol Adv. 2020. PMID: 32642739 Free PMC article. Review.
-
Management of neurofibromatosis type 1-associated plexiform neurofibromas.Neuro Oncol. 2022 Nov 2;24(11):1827-1844. doi: 10.1093/neuonc/noac146. Neuro Oncol. 2022. PMID: 35657359 Free PMC article. Review.
References
-
- Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 2013; 115: 939–955. - PubMed
-
- De Vet HCW, Terwee CB, Mokkink LB, et al. Measurement in medicine: a practical guide. Cambridge: Cambridge University Press, 2011.
-
- Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010; 63(7): 737–745. - PubMed
-
- Stokes EK. Rehabilitation outcome measures. Edinburgh: Churchill Livingstone, 2011, pp. 27–34.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials